Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer

  • STATUS
    Recruiting
  • End date
    Sep 22, 2023
  • participants needed
    304
  • sponsor
    AstraZeneca
Updated on 4 June 2021
Investigator
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (5.4 mi away) Contact
+16 other location

Summary

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

Description

This is a multicentre dose escalation and expansion, first-in-human study designed to evaluate the safety and tolerability of AZD9833, alone (Parts A and B) or in combination with palbociclib (Parts C and D) or in combination with everolimus (Parts E and F) or in combination with abemaciclib (Parts G and H), in women with endocrine-resistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent.

Details
Condition ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer, ER+ HER2- Advanced Breast Cancer
Treatment AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib dose escalation, AZD9833 with abemaciclib
Clinical Study IdentifierNCT03616587
SponsorAstraZeneca
Last Modified on4 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

\. Disease suitable for paired baseline and on-study tumour biopsies
\. Washout from prior fulvestrant: 6 months
\. Washout from prior tamoxifen: 4 months
\. Signed written informed consent for tumour biopsies
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note